Bio-Rad Laboratories reported modest Q3 growth, beating analyst estimates. Challenges in biotech funding and academic research led to a 3% stock drop. The company maintained its 2025 guidance, forecasting flat to 1% revenue growth. Investors should consider other high-return stocks identified by analysts.